189 related articles for article (PubMed ID: 31990936)
1. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
[TBL] [Abstract][Full Text] [Related]
2. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
[TBL] [Abstract][Full Text] [Related]
3. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
[TBL] [Abstract][Full Text] [Related]
5. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
Tahara N; Yamagishi SI; Bekki M; Kodama N; Nakamura T; Sugiyama Y; Oshige T; Kumashiro Y; Honda A; Tahara A; Igata S; Fukumoto Y
Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
[TBL] [Abstract][Full Text] [Related]
6. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
[TBL] [Abstract][Full Text] [Related]
7. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.
Kurozumi A; Okada Y; Arao T; Kobayashi T; Masuda D; Yamashita S; Tanaka Y
J Diabetes Investig; 2018 Mar; 9(2):360-365. PubMed ID: 28853228
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Yang HK; Min KW; Park SW; Chung CH; Park KS; Choi SH; Song KH; Kim DM; Lee MK; Sung YA; Baik SH; Kim IJ; Cha BS; Park JH; Ahn YB; Lee IK; Yoo SJ; Kim J; Park IeB; Park TS; Yoon KH
Endocr J; 2015; 62(5):449-62. PubMed ID: 25819061
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
Yano W; Inoue N; Ito S; Itou T; Yasumura M; Yoshinaka Y; Hagita S; Goto M; Nakagawa T; Inoue K; Tanabe S; Kaku K
J Diabetes Investig; 2017 Mar; 8(2):155-160. PubMed ID: 27860391
[TBL] [Abstract][Full Text] [Related]
11. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
[TBL] [Abstract][Full Text] [Related]
12. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
13. [Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin].
Tsubamoto Y; Goto M
Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):339-49. PubMed ID: 23749075
[No Abstract] [Full Text] [Related]
14. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
Goto M; Furuta S; Yamashita S; Hashimoto H; Yano W; Inoue N; Kato N; Kaku K
J Diabetes Investig; 2018 Nov; 9(6):1261-1269. PubMed ID: 29754453
[TBL] [Abstract][Full Text] [Related]
16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
17. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.
Abe T; Matsubayashi Y; Muragishi S; Yoshida A; Suganami H; Furusawa K; Fujihara K; Tanaka S; Kaku K; Sone H
J Diabetes Investig; 2021 Oct; 12(10):1805-1815. PubMed ID: 33751849
[TBL] [Abstract][Full Text] [Related]
19. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
20. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
